NCT03608618View on ClinicalTrials.gov

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

PHASE1TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 27, 2018

Primary Completion Date

February 11, 2021

Study Completion Date

August 24, 2021

Conditions
Peritoneal MesotheliomaFallopian Tube AdenocarcinomaAdenocarcinoma of the OvaryPrimary Peritoneal Carcinoma
Interventions
BIOLOGICAL

MCY-M11

Intraperitoneal administration

DRUG

Cyclophosphamide

Intravenous administration for preconditioning

Trial Locations (4)

20892

National Cancer Institute, National Institutes of Health, Rockville

63110

Washington University at St. Louis, St Louis

02114

Massachusetts General Hospital, Boston

07601

Hackensack University Medical Center, Hackensack

Sponsors

Lead Sponsor

MaxCyte, Inc.
All Listed Sponsors
collaborator

CTI Clinical Trial and Consulting Services

OTHER

lead

MaxCyte, Inc.

INDUSTRY